EU ups contribution to COVAX to 500 million euros to secure COVID-19 vaccines for low and middle-income countries
The European Union announced yesterday that it will contribute an additional 100 million euros ($117.6 million) in grant funding to support the COVAX Facility to secure access to the future COVID-19 vaccine in low and middle-income countries.
The funds will complement the 400 million euros in guarantees the EU already committed for COVAX, making the Union one of the leading donors. With this new contribution, the EU is further stepping up investment in support of the global recovery.
The President of the European Commission, Ursula von der Leyen, made the announcement on Thursday at the virtual Paris Peace Forum, where world leaders and international organizations are discussing the global response and the recovery from the pandemic. Also attending were the Commissioner for International Partnerships, Jutta Urpilainen, and the Commissioner for Health and Food Safety, Stella Kyriakides.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze